Kaleido Biosciences, Inc. (KLDO)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Aug 14, 2025, 8:00 PM EDT
Kaleido Biosciences Company Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.
The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.
It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.
The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen.
Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Kaleido Biosciences, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
Contact Details
Address: 65 Hayden Avenue Lexington, Delaware 02421 United States | |
| Phone | 617 674 9000 |
| Website | kaleido.com |
Stock Details
| Ticker Symbol | KLDO |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US4833471000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Research & Development and Head of Development |